Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Clas Sonesson"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 3, Pp n/a-n/a (2021)
Abstract The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist
Externí odkaz:
https://doaj.org/article/287aae86fd3f4466a3d910fdf394b552
Autor:
Joakim Tedroff, Folke Sjöberg, Susanna Waters, Erik Rein-Hedin, Nicholas Waters, Fredrik Huss, Clas Sonesson
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1485-1494
Pirepemat (IRL752) is a cortical enhancer being developed for the prevention of falls in patients with Parkinson disease. This first-in-human, randomized, double-blind, placebo-controlled phase 1 study evaluated safety, tolerability, and pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac12d127e99fbfb490325978af0e87a3
https://doi.org/10.1002/cpdd.959
https://doi.org/10.1002/cpdd.959
Autor:
Jenny Gunnergren, Malin Edling, Stephan Hjorth, Anne Fagerberg, Samantha L. McLean, Nicholas Waters, Boel Svanberg, Peder Svensson, Joanna C. Neill, Elisabeth Ljung, Clas Sonesson, Ben Grayson, Nagi F Idris, Susanna Waters, Joakim Tedroff
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:404-419
Here we describe for the first time the distinctive pharmacological profile for (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752), a new phenyl-pyrrolidine derivative with regioselective central nervous system transmission-enhancing propertie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b198d7b7818290225bea3098e18b26
https://doi.org/10.1124/jpet.120.000037
https://doi.org/10.1124/jpet.120.000037
Autor:
Anne Fagerberg, Elisabeth Ljung, Nicholas Waters, Peder Svensson, Stephan Hjorth, Jenny Gunnergren, Malin Edling, Joakim Tedroff, Susanna Waters, Johan Kullingsjö, Manolo Carta, Boel Svanberg, Clas Sonesson
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:113-125
IRL790 ([2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine, mesdopetam) is a novel compound in development for the clinical management of motor and psychiatric disabilities in Parkinson disease. The discovery of IRL790 was made applying a syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca2cf245851fbcf28be5b8638b8a736
https://doi.org/10.1124/jpet.119.264226
https://doi.org/10.1124/jpet.119.264226
Autor:
Per, Svenningsson, Per, Odin, Nil, Dizdar, Anders, Johansson, Sotirios, Grigoriou, Panagiota, Tsitsi, Klas, Wictorin, Filip, Bergquist, Dag, Nyholm, Juha, Rinne, Fredrik, Hansson, Clas, Sonesson, Joakim, Tedroff, Christian, Carlström
Publikováno v:
Movement disorders : official journal of the Movement Disorder SocietyReferences. 35(6)
Background: IRL752 is a novel small-molecule compound that acts to regioselectively enhance norepinephrine, dopamine, and acetylcholine neurotransmission in the cerebral cortex. Objective: The primary objective of the trial was to investigate the saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23398f5d4d68c15916ec80c47e494f7d
https://pubmed.ncbi.nlm.nih.gov/32198802
https://pubmed.ncbi.nlm.nih.gov/32198802
Publikováno v:
Journal of Huntington's Disease
Despite advances in understanding the pathophysiology of Huntington’s disease (HD), there are currently no effective pharmacological agents available to treat core symptoms or to stop or prevent the progression of this hereditary neurodegenerative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7221d80d9ae3fc0ecfd7c23e2523de62
https://doi.org/10.3233/jhd-170267
https://doi.org/10.3233/jhd-170267
Autor:
Henrik Ponten, Clas Sonesson, Theresa Andreasson, Ylva Sunesson, Johan Kullingsjö, Elisabeth Ljung, Peder Svensson, Nicholas Waters, Susanna Waters
Publikováno v:
ACS Chemical Neuroscience. 8:785-797
This paper describes the application of in vivo systems response profiling in CNS drug discovery by a process referred to as the Integrative Screening Process. The biological response profile, treated as an array, is used as major outcome for selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57de92644a871ce1918b7f86b7a9d120
https://doi.org/10.1021/acschemneuro.6b00371
https://doi.org/10.1021/acschemneuro.6b00371
Autor:
Panagiota Tsitsi, Fredrik Hansson, Clas Sonesson, Per Svenningsson, Anders Johansson, Dag Nyholm, Joakim Tedroff
Publikováno v:
npj Parkinson's Disease, Vol 4, Iss 1, Pp 1-5 (2018)
NPJ Parkinson's Disease
NPJ Parkinson's Disease
IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf03e8db0b8664d6d23feca171c58872
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371819
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371819
Publikováno v:
European Journal of Medicinal Chemistry. 62:241-255
A series of mono-substituted 4-phenylpiperidines and -piperazines have been synthesized and their effects on the dopaminergic system tested in vivo. The structure activity relationship (SAR) revealed that the position and physicochemical character of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fded35166229251075e71d1dd1c274a
https://doi.org/10.1016/j.ejmech.2012.12.031
https://doi.org/10.1016/j.ejmech.2012.12.031
Publikováno v:
Journal of Medicinal Chemistry. 55:3242-3249
A series of para-substituted 4-phenylpiperidines/piperazines have been synthesized and their affinity to recombinant rat cerebral cortex monoamine oxidases A (MAO A) and B (MAO B) determined. Para-substituents with low dipole moment increased the aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f98c511b2729718b77af019d528e6bc
https://doi.org/10.1021/jm201692d
https://doi.org/10.1021/jm201692d